Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Phase 1/2 Active not recruiting 20 enrolled Peter MacCallum Cancer Centre, Australia E.J. Whitten Foundation Prostate Cancer Research Centre · collab Endocyte · collab Medical Research Future Fund · collab Movember Foundation · collab

NaSingle-groupOpen-labelTreatment

Summary

This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)

Timeline

Start: 2020-08-06
Primary completion: 2022-12-22
Completion: 2025-08-30

Publications

Eapen RS, Buteau JP, Jackson P, Mitchell C, Oon SF, Alghazo O, McIntosh L, Dhiantravan N, Scalzo MJ, O'Brien J, Sandhu S, Azad AA, Williams SG, Sharma G, Haskali MB, Bressel M, Chen K, Jenjitranant P, McVey A, Moon D, Lawrentschuk N, Neeson PJ, Murphy DG, Hofman MS. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2024 Mar;85(3):217-226. doi: 10.1016/j.eururo.2023.08.026. Epub 2023 Oct 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-PSMA-617	Other / unclassified	5000 mbq	—

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Summary

Timeline

Publications

Drugs

Indications